Actualités

Intuitive Surgical faces mixed international trends as China pressure and Japan delays cloud otherwise strong OUS growth outlook.

Intuitive Surgical’s first quarter results for 2026 exceeded Wall Street’s expectations, with management crediting the outcome to strong global procedure growth and expansion of the da Vinci and Ion platforms. CEO David Rosa pointed to a 17% increase in total procedures, including “broad-based adoption across da Vinci and Ion as customers continue to advance minimally invasive care.” The company also highlighted notable gains in after-hours and non-urology procedures, as well as expanding uptake

Intuitive Surgical recently reported past first-quarter 2026 results showing revenue of US$2,770.8 million and net income of US$821.5 million, alongside completing a multi-year buyback of 29,440,210 shares for US$9.08 billion. The combination of higher earnings per share and a reduced share count from the long-running repurchase program highlights management’s focus on reinforcing shareholder value through both operating performance and capital allocation. We’ll now examine how this stronger...

Robotic surgery’s market leader has had a rough start to 2026, but our model sees the pullback as an opportunity. Intuitive Surgical (NASDAQ:ISRG) trades at $482.22 after a 14.86% year-to-date decline, even as Q1 procedure growth and da Vinci 5 adoption continue to accelerate. Our 24/7 Wall St. price target for Intuitive Surgical is $615.93, ... Why Intuitive Surgical Is a Strong Buy as Robotic Surgery Adoption Accelerates

Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.

Intuitive Surgical's strong Q1 results, rising procedures, and raised outlook highlight accelerating growth, while Boston Scientific faces headwinds and tempered guidance.

Intuitive Surgical (ISRG) possesses solid growth attributes, which could help it handily outperform the market.